We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Data Science & Analytics/Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity
PeriodicalsData Science & Analytics

Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity

Checking your access to this record.

Abstract & Overview

Cyclooxygenase-2 (COX-2), an inducible form of the enzyme that catalyzes the first step in the synthesis of prostanoids, is associated with inflammatory diseases and carcinogenesis, which is suspected to promote angiogenesis and tissue invasion of tumors and resistance to apoptosis. Meanwhile, COX-2 contributes to immune evasion and resistance to cancer immunotherapy, which plays a crucial role in the innate and adaptive immune response. The activity of COX-2-PGE2-EP signal pathway can suppress Dendritic cells (DCs), natural killer (NK), T cells, type-1 immunity excluding type-2 immunity which promote tumor immune evasion. COX-2 and the prostaglandin cascade play important roles in the "inflammogenesis of cancer". In addition, COX-inhibitors can inhibit tumor immune evasion. Therefore, we can exert the COX-inhibitors to facilitate the patients to benefit from addition of COX-inhibitors to standard cytotoxic therapy.

Cite this record

Bing Liu, Liyan Qu, Shigui Yan (2015). Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell International, 15(1), 106–106. https://doi.org/10.1186/s12935-015-0260-7

Copy in another style

Liu, B., Qu, L., & Yan, S. (2015). Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell International, 15(1), 106–106. https://doi.org/10.1186/s12935-015-0260-7
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.